# A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

> **NCT05452239** · PHASE4 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 608 (actual)

## Conditions studied

- Migraine
- Medication Overuse Headache

## Interventions

- **DRUG:** Eptinezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05452239
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2024-10-22
- **Final completion:** 2025-03-13
- **Target enrollment:** 608 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05452239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05452239, "A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05452239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*